Polyomavirus BK Neutralizing Activity in Human Immunoglobulin Preparations
- 27 June 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (12) , 1462-1465
Abstract
Background. Polyomavirus BK (BKV) infection can cause nephropathy in the allograft kidney. No well-established drug treatment is available at this time. Human intravenous immunoglobulins (IVIG) have been used as an empiric therapy without proof of effectiveness. Methods. We tested five lots of commercially available IVIG preparations from two different suppliers for polyomavirus neutralizing activity. BKV and mouse polyomavirus were used to infect human and murine host cells, respectively, with or without prior treatment with IVIG. Neutralization activity was measured by quantitation of viral DNA after 7 days in culture. Results. Coincubation of BKV but not mouse polyomavirus with clinically relevant concentrations of IVIG derived from healthy and hepatitis B vaccinated subjects caused more than 90% inhibition of viral DNA yield after 7 days in culture. Consistent with a direct neutralizing mechanism, this effect was significantly diminished if viral infection was performed in immunoglobulin pretreated cells or if immunoglobulin treatment was delayed 2 hr after addition of infectious virus. Conclusion. Human IVIG preparations contain BKV neutralizing antibodies. Data on neutralizing capacity of these antibodies are presented to aid dose exploration in clinical trials seeking to validate the use of IVIG in patients with BKV infection.Keywords
This publication has 20 references indexed in Scilit:
- Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodiesJournal of General Virology, 2009
- Intravenous immunoglobulin as rescue therapy for BK virus nephropathyPediatric Transplantation, 2009
- Intravenous immunoglobulin as treatment for BK virus: NephropathyPediatric Transplantation, 2009
- BK virus antibody titers and intensity of infections after renal transplantationJournal of Clinical Virology, 2008
- Structure of Antibody-Neutralized Murine Norovirus and Unexpected Differences from Viruslike ParticlesJournal of Virology, 2008
- In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective TitersJournal of Virology, 2008
- Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody ResponsesJournal of Virology, 2008
- Quantitation of HLA Proteins Incorporated by Human Immunodeficiency Virus Type 1 and Assessment of Neutralizing Activity of Anti-HLA AntibodiesJournal of Virology, 2008
- Utilization of Complement-Dependent Cytotoxicity To Measure Low Levels of Antibodies: Application to Nonstructural Protein 1 in a Model of Japanese Encephalitis VirusClinical and Vaccine Immunology, 2008
- A Mouse Model for Polyomavirus-Associated Nephropathy of Kidney TransplantsAmerican Journal of Transplantation, 2006